Business / Finance

RSS

Exact Sciences reports total revenues of $1.0 million for third quarter 2012

Exact Sciences Corp. today announced its financial results for the quarter ended Sept. 30, 2012.

30 Oct 2012

Cardinal Health increases quarterly dividend to $0.275 per share

Cardinal Health today announced that its board of directors has approved a 16 percent increase in the company's quarterly dividend to $0.275 per share, or $1.10 per share on an annualized basis.

30 Oct 2012

Cardinal Health fiscal 2013 first-quarter revenue increases 11% to $25.9B

Cardinal Health today reported fiscal year 2013 first-quarter revenue of $25.9 billion and an 11 percent increase in non-GAAP diluted earnings per share (EPS) from continuing operations to $0.81.

30 Oct 2012

Hospice Care of Kansas announces name change

Harden Healthcare, a Texas-based senior healthcare services provider with operations in 14 states, announced today that its subsidiary, Hospice Care of Kansas, will change its name to Harden Hospice Kansas effective immediately.

30 Oct 2012

Tenet exercises option to extend previously announced cash tender offer

Tenet Healthcare Corporation announced today that it has exercised its option to extend its previously announced cash tender offer to purchase any and all of the $216.361 million aggregate principal amount outstanding of its 7.375% Senior Notes due 2013 until 12:00 midnight, New York City time, on October 31, 2012.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Bayer HealthCare signs merger agreement to acquire Schiff Nutrition International

Bayer HealthCare LLC has signed a merger agreement to acquire Schiff Nutrition International, Inc., a leading company offering vitamins and nutritional supplements in the United States and other countries.

30 Oct 2012

MiMedx third quarter revenue increases 270% to $8.0 million

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended September 30, 2012.

30 Oct 2012

Luminex third quarter revenue increases 10% to $50.0 million

Luminex Corporation today announced financial results for the third quarter ended September 30, 2012.

From Luminex 30 Oct 2012

UMIA, The Doctors Company enter merger agreement

Utah Medical Insurance Association (UMIA), the leading provider of medical professional liability insurance for physicians in Utah, Montana, and Wyoming, and The Doctors Company, the nation's largest insurer of physician and surgeon medical professional liability, announced today that they have entered into a merger agreement pursuant to which UMIA will be acquired by The Doctors Company through its wholly owned subsidiary, Underwriter for the Professions Insurance Company.

30 Oct 2012

Par to acquire Handa's ANDA for generic Seroquel XR

Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC to acquire Handa's Abbreviated New Drug Application (ANDA) for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR.

29 Oct 2012

Neuros Medical honored as most promising startup

Neuros Medical, Inc., a medical device company, was presented the 2012 Gold Electrode Award for Most Promising Startup at the Neurotech Leaders Forum conference in San Francisco. The award is given by Neurotech Reports, and highlights a company in the neuromodulation industry that holds the most promise.

29 Oct 2012

Range of biopharma solutions from Malvern Instruments extended by distribution agreement with Affinity Biosensors

Materials characterization company Malvern Panalytical. (Malvern Panalytical, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern Panalytical offers to the biopharmaceutical sector.

From Malvern Panalytical 29 Oct 2012

Haemonetics second quarter 2013 net revenue increases 22% to $218.2 million

Haemonetics Corporation today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.

29 Oct 2012

Quality Systems second quarter revenues increase 8% to $116.1 million

Quality Systems, Inc. announced today results for its fiscal 2013 second quarter ended September 30, 2012.

26 Oct 2012

Thrasos completes $35 Million financing for development of THR-184 against AKI

Thrasos Therapeutics announced that it has completed a $35 Million (U.S.) financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

25 Oct 2012

DSM extends license to supply CarboSil® TSPCU for use in AxioMed Spine Corporation’s Freedom® Spinal Discs

DSM, a global leader in biomedical materials sciences, and AxioMed Spine Corporation, an innovator in the field of spinal implant devices, today announced that they have revised and extended an existing licensing and supply agreement. DSM will supply its proprietary CarboSil®Thermoplastic Silicone-Polycarbonate-urethane material for use in AxioMed’s Freedom® Lumbar and Freedom® Cervical Discs.

24 Oct 2012

ZOLL Medical announces new Tokyo-based subsidiary

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions and a wholly owned U.S. subsidiary of Asahi Kasei, has established Asahi Kasei ZOLL Medical Corporation (AZM) as its Japanese subsidiary effective November 5.

24 Oct 2012

Financial environment presents opportunities as well as challenges

Leading biotechnology executive Dr Deborah Rathjen has called on the industry to look at the opportunities that exist in a post-GFC environment, not just to focus on the negatives.

23 Oct 2012

Pfizer announces intention to acquire NextWave

Pfizer Inc. today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

23 Oct 2012